Shares of Neurotrope Inc (NASDAQ:NTRP) have earned an average broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation.
Zacks has also assigned Neurotrope an industry rank of 111 out of 255 based on the ratings given to its competitors.
Separately, Zacks Investment Research cut Neurotrope from a “buy” rating to a “hold” rating in a research note on Friday, November 1st.
Shares of Neurotrope stock traded up $0.01 during trading on Friday, hitting $1.15. The stock had a trading volume of 2,099 shares, compared to its average volume of 193,199. Neurotrope has a 12 month low of $0.63 and a 12 month high of $8.40. The firm’s fifty day simple moving average is $0.97 and its 200-day simple moving average is $2.68. The stock has a market cap of $14.94 million, a PE ratio of -0.84 and a beta of 1.98.
Neurotrope (NASDAQ:NTRP) last announced its earnings results on Tuesday, November 12th. The company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.03.
Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases.
Recommended Story: Trading Penny Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.